University of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America.
University of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America.
Schizophr Res. 2018 Dec;202:113-119. doi: 10.1016/j.schres.2018.07.012. Epub 2018 Jul 11.
Olfactory functioning is a promising biomarker for psychosis in 22q11.2 deletion syndrome (22q11DS) but has not been well studied to date. This is a pilot effort to evaluate the potential for tests of olfactory functioning to contribute to risk and resilience prediction in 22q11DS, and is the first study to evaluate relationships among olfactory deficits, cognition and psychosis-spectrum symptoms. Odor identification and discrimination were evaluated in 32 individuals with 22q11DS and 110 healthy comparison subjects (HC). Individuals with 22q11DS also underwent cognitive testing with the Penn Computerized Neurocognitive Battery, which evaluates executive functioning, episodic memory, complex cognition, and social cognition. Positive, negative, disorganized and general psychosis-spectrum symptoms were rated according to the Scale of Prodromal Symptoms. Age-normalized scores were calculated for odor identification and discrimination based on normative data. Both odor identification (p < 0.001, Cohen's d = -2.15, 95% CI [-2.62, -1.68]) and discrimination (p < 0.001, Cohen's d = -1.81, 95% CI [-2.26, -1.35]) were significantly impaired in 22q11DS relative to HC. There were no sex differences in either group. Neither odor identification nor discrimination was correlated with overall cognition or any specific cognitive domain in 22q11DS. Impairment in odor discrimination was correlated with higher negative and overall psychosis-spectrum symptoms. There was no significant effect of catechol-O-methyltransferase Val(158)Met genotype or presence of velopharyngeal insufficiency on olfactory functioning. Olfactory deficits, particularly olfactory discrimination, are robust in 22q11DS and appear to be independent of cognitive deficits. They are also clinically relevant and related to psychosis-spectrum symptoms. Olfactory functioning appears to be a promising biomarker for psychosis in 22q11DS.
嗅觉功能是 22q11.2 缺失综合征(22q11DS)中精神分裂症的一个很有前途的生物标志物,但迄今为止研究还不够充分。本研究旨在评估嗅觉功能测试在 22q11DS 中的风险和适应能力预测中的潜在作用,也是评估嗅觉缺陷、认知和精神病症状之间关系的第一项研究。研究评估了 32 名 22q11DS 患者和 110 名健康对照组(HC)的嗅觉识别和辨别能力。22q11DS 患者还接受了宾夕法尼亚计算机化神经认知测试,该测试评估了执行功能、情景记忆、复杂认知和社会认知。根据前驱症状量表评估阳性、阴性、紊乱和一般精神病症状谱。根据正常数据,计算了年龄标准化的嗅觉识别和辨别分数。与 HC 相比,22q11DS 患者的嗅觉识别(p<0.001,Cohen's d=-2.15,95%CI[-2.62,-1.68])和辨别(p<0.001,Cohen's d=-1.81,95%CI[-2.26,-1.35])均显著受损。两组之间没有性别差异。在 22q11DS 中,嗅觉识别和辨别均与整体认知或任何特定认知领域均无相关性。嗅觉辨别障碍与更高的阴性和总体精神病症状谱相关。儿茶酚-O-甲基转移酶 Val(158)Met 基因型或软腭功能不全的存在对嗅觉功能均无显著影响。22q11DS 患者嗅觉缺陷,尤其是嗅觉辨别能力,非常明显,且似乎与认知缺陷无关。嗅觉缺陷与精神病症状谱相关,具有临床意义。嗅觉功能似乎是 22q11DS 中精神分裂症的一个很有前途的生物标志物。